{"protocolSection": {"identificationModule": {"nctId": "NCT01545388", "orgStudyIdInfo": {"id": "0431A-136"}, "secondaryIdInfos": [{"id": "ONO-5435A", "type": "OTHER", "domain": "ONO Pharmaceutical Company, Ltd."}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)", "officialTitle": "A Phase III, Randomized, Placebo and Active-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of the Addition of Metformin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Sitagliptin Monotherapy"}, "statusModule": {"statusVerifiedDate": "2018-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-02-23", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2013-03-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-03-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-03-01", "studyFirstSubmitQcDate": "2012-03-05", "studyFirstPostDateStruct": {"date": "2012-03-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-02-10", "resultsFirstSubmitQcDate": "2014-02-10", "resultsFirstPostDateStruct": {"date": "2014-03-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-07-24", "lastUpdatePostDateStruct": {"date": "2018-08-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will evaluate the effect of the addition of metformin once daily (q.d.) or twice daily (b.i.d.) to sitagliptin monotherapy in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control with diet/exercise therapy and sitagliptin monotherapy. The primary hypotheses are that the addition of metformin 250 mg b.i.d. or metformin 500 mg q.d. is superior to the addition of placebo on the change from baseline in hemoglobin A1c (HbA1c) at 24 weeks and that the addition of metformin 500 mg q.d. is non-inferior to the addition of metformin 250 mg b.i.d. on the change from baseline in HbA1c at 24 weeks."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 337, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Metformin 500 mg q.d.", "type": "EXPERIMENTAL", "description": "Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.", "interventionNames": ["Drug: Sitagliptin", "Drug: Metformin", "Drug: Placebo"]}, {"label": "Metformin 250 mg b.i.d.", "type": "EXPERIMENTAL", "description": "Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.", "interventionNames": ["Drug: Sitagliptin", "Drug: Metformin", "Drug: Placebo"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.", "interventionNames": ["Drug: Sitagliptin", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin", "description": "Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)", "armGroupLabels": ["Metformin 250 mg b.i.d.", "Metformin 500 mg q.d.", "Placebo"], "otherNames": ["MK-0431/ONO-5435"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks", "armGroupLabels": ["Metformin 500 mg q.d."]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks", "armGroupLabels": ["Metformin 250 mg b.i.d."]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo to match metformin 250 mg tablets, orally, for 24 weeks", "armGroupLabels": ["Metformin 250 mg b.i.d.", "Metformin 500 mg q.d.", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)", "description": "Based on a constrained longitudinal data analysis (cLDA) model with terms for treatment, other prior antihyperglycemic agent (AHA) therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.", "timeFrame": "Baseline and Week 24"}, {"measure": "Percentage of Participants Who Experienced at Least One Adverse Event", "timeFrame": "Up to 26 weeks"}, {"measure": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", "timeFrame": "Up to 24 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)", "description": "Based on a cLDA model with terms for treatment, other prior AHA therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.", "timeFrame": "Baseline and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 Diabetes Mellitus (T2DM)\n* Currently being treated with diet/exercise and on stable dose of sitagliptin for \u2265 4 weeks, on any additional oral hypoglycemic agent (AHA) in the prior 8 weeks, and HbA1c \u2265 6.0% and \u2264 9.0%; or\n* Currently being treated with diet/exercise and on stable dose of sitagliptin for \u2265 10 weeks, not on any additional oral AHA in the prior 8 weeks, and HbA1c \u2265 6.5% and \\< 10.0%\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus,\n* Secondary diabetes mellitus, or\n* Gestational diabetes mellitus", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "74 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "referencesModule": {"availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/study.html?id=0431A-136&kw=0431A-136&tab=access"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Metformin 500 mg q.d.", "description": "Participants received sitagliptin daily at pre-study dose, 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening."}, {"id": "FG001", "title": "Metformin 250 mg b.i.d.", "description": "Participants received sitagliptin daily at pre-study dose, 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening."}, {"id": "FG002", "title": "Placebo", "description": "Participants received sitagliptin daily at pre-study dose, 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "138"}, {"groupId": "FG001", "numSubjects": "133"}, {"groupId": "FG002", "numSubjects": "66"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "130"}, {"groupId": "FG001", "numSubjects": "122"}, {"groupId": "FG002", "numSubjects": "58"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Participant moved or relocated", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All participants as treated population defined as all randomized participants.", "groups": [{"id": "BG000", "title": "Metformin 500 mg q.d.", "description": "Participants received sitagliptin daily at pre-study dose, 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening."}, {"id": "BG001", "title": "Metformin 250 mg b.i.d.", "description": "Participants received sitagliptin daily at pre-study dose, 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening."}, {"id": "BG002", "title": "Placebo", "description": "Participants received sitagliptin daily at pre-study dose, 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "133"}, {"groupId": "BG002", "value": "66"}, {"groupId": "BG003", "value": "337"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.46", "spread": "9.61"}, {"groupId": "BG001", "value": "59.65", "spread": "9.22"}, {"groupId": "BG002", "value": "60.05", "spread": "9.30"}, {"groupId": "BG003", "value": "59.65", "spread": "9.37"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "126"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "86"}, {"groupId": "BG001", "value": "87"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "211"}]}]}]}, {"title": "Hemoglobin A1c (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent of glycosylated hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.60", "spread": "0.83"}, {"groupId": "BG001", "value": "7.40", "spread": "0.68"}, {"groupId": "BG002", "value": "7.53", "spread": "0.77"}, {"groupId": "BG003", "value": "7.51", "spread": "0.76"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "158.58", "spread": "32.45"}, {"groupId": "BG001", "value": "148.98", "spread": "26.27"}, {"groupId": "BG002", "value": "154.27", "spread": "27.51"}, {"groupId": "BG003", "value": "153.95", "spread": "29.42"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)", "description": "Based on a constrained longitudinal data analysis (cLDA) model with terms for treatment, other prior antihyperglycemic agent (AHA) therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.", "populationDescription": "Per-protocol population defined as all randomized participants who had at least one measurement (baseline or post-randomization), with participants and/or selected data excluded due to protocol violations.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent of glycosylated hemoglobin", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Metformin 500 mg q.d.", "description": "Participants received sitagliptin daily at pre-study dose, 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening."}, {"id": "OG001", "title": "Metformin 250 mg b.i.d.", "description": "Participants received sitagliptin daily at pre-study dose, 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening."}, {"id": "OG002", "title": "Placebo", "description": "Participants received sitagliptin daily at pre-study dose, 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "130"}, {"groupId": "OG002", "value": "66"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.434", "lowerLimit": "-0.553", "upperLimit": "-0.315"}, {"groupId": "OG001", "value": "-0.587", "lowerLimit": "-0.708", "upperLimit": "-0.467"}, {"groupId": "OG002", "value": "0.091", "lowerLimit": "-0.073", "upperLimit": "0.255"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "cLDA", "statisticalComment": "Based on a cLDA model with the terms listed above and a constraint that the mean baseline is the same for all treatment groups.", "paramType": "Difference in least squares means", "paramValue": "-0.678", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.868", "ciUpperLimit": "-0.489"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "cLDA", "statisticalComment": "Based on a cLDA model with the terms listed above and a constraint that the mean baseline is the same for all treatment groups.", "paramType": "Difference in least squares means", "paramValue": "-0.525", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.713", "ciUpperLimit": "-0.337"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The non-inferiority margin (\u0394) is set as 0.3% to show the non-inferiority of metformin 500 mg q.d. to metformin 250 mg b.i.d.", "paramType": "Difference in least squares means", "paramValue": "0.153", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.000", "ciUpperLimit": "0.306"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)", "description": "Based on a cLDA model with terms for treatment, other prior AHA therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.", "populationDescription": "Per-protocol population defined as all randomized participants who had at least one measurement (baseline or post-randomization), with participants and/or selected data excluded due to protocol violations.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Metformin 500 mg q.d.", "description": "Participants received sitagliptin daily at pre-study dose, 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening."}, {"id": "OG001", "title": "Metformin 250 mg b.i.d.", "description": "Participants received sitagliptin daily at pre-study dose, 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening."}, {"id": "OG002", "title": "Placebo", "description": "Participants received sitagliptin daily at pre-study dose, 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "130"}, {"groupId": "OG002", "value": "66"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.02", "lowerLimit": "-13.74", "upperLimit": "-4.30"}, {"groupId": "OG001", "value": "-11.27", "lowerLimit": "-16.07", "upperLimit": "-6.46"}, {"groupId": "OG002", "value": "7.32", "lowerLimit": "0.86", "upperLimit": "13.79"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "cLDA", "statisticalComment": "Based on a cLDA model with the terms listed above and a constraint that the mean baseline is the same for all treatment groups.", "paramType": "Difference in least squares means", "paramValue": "-18.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.94", "ciUpperLimit": "-11.24"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "cLDA", "statisticalComment": "Based on a cLDA model with the terms listed above and a constraint that the mean baseline is the same for all treatment groups.", "paramType": "Difference in least squares means", "paramValue": "-16.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.62", "ciUpperLimit": "-9.06"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares mean", "paramValue": "2.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.63", "ciUpperLimit": "8.14"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced at Least One Adverse Event", "populationDescription": "All participants as treated defined as all randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 26 weeks", "groups": [{"id": "OG000", "title": "Metformin 500 mg q.d.", "description": "Participants received sitagliptin daily at pre-study dose, 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening."}, {"id": "OG001", "title": "Metformin 250 mg b.i.d.", "description": "Participants received sitagliptin daily at pre-study dose, 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening."}, {"id": "OG002", "title": "Placebo", "description": "Participants received sitagliptin daily at pre-study dose, 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "133"}, {"groupId": "OG002", "value": "66"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "65.9"}, {"groupId": "OG001", "value": "67.7"}, {"groupId": "OG002", "value": "60.6"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", "populationDescription": "All participants as treated defined as all randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 24 weeks", "groups": [{"id": "OG000", "title": "Metformin 500 mg q.d.", "description": "Participants received sitagliptin daily at pre-study dose, 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening."}, {"id": "OG001", "title": "Metformin 250 mg b.i.d.", "description": "Participants received sitagliptin daily at pre-study dose, 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening."}, {"id": "OG002", "title": "Placebo", "description": "Participants received sitagliptin daily at pre-study dose, 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "133"}, {"groupId": "OG002", "value": "66"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 26 weeks", "description": "All participants as treated defined as all randomized participants who received at least one dose of study treatment.", "eventGroups": [{"id": "EG000", "title": "Metformin 500 mg q.d.", "description": "Participants received sitagliptin daily at pre-study dose, 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.", "seriousNumAffected": 4, "seriousNumAtRisk": 138, "otherNumAffected": 29, "otherNumAtRisk": 138}, {"id": "EG001", "title": "Metformin 250 mg b.i.d.", "description": "Participants received sitagliptin daily at pre-study dose, 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.", "seriousNumAffected": 2, "seriousNumAtRisk": 133, "otherNumAffected": 35, "otherNumAtRisk": 133}, {"id": "EG002", "title": "Placebo", "description": "Participants received sitagliptin daily at pre-study dose, 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.", "seriousNumAffected": 0, "seriousNumAtRisk": 66, "otherNumAffected": 8, "otherNumAtRisk": 66}], "seriousEvents": [{"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 138}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 133}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 66}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 138}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 133}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 66}]}, {"term": "Sternal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 138}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 133}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 66}]}, {"term": "Brain stem infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 138}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 133}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 66}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 138}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 133}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 66}]}, {"term": "Interstitial lung disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 138}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 133}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 66}]}], "otherEvents": [{"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 138}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 133}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 66}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 17, "numAtRisk": 138}, {"groupId": "EG001", "numEvents": 31, "numAffected": 28, "numAtRisk": 133}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 66}]}, {"term": "Upper respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 8, "numAtRisk": 138}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 133}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 66}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.\n\nAny information identified by the sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Japan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}